Bryostatin Improves Cognition in Patients with Advanced Alzheimer’s, Analysis Finds

Bryostatin Improves Cognition in Patients with Advanced Alzheimer’s, Analysis Finds
Bryostatin, Neurotrope Bioscience’s investigational therapy, was associated with improved cognition in advanced Alzheimer's disease patients in post-hoc (after-the-fact) analysis of a Phase 2 trial. Results from this study were presented at the Sachs' Neuroscience Innovation Forum on Jan. 7 in San Francisco, California. Bryostatin-1 is a compound known as a protein kinase C (PKC) modulator exerting its effect in specific pathways in the brain. Preclinical studies have shown the compound can generate new connections between nerve cells and also prevent nerve cells' death, thereby improving cognition. The mol
Subscribe or to access all post and page content.

One comment

  1. Georges Tony MARCEL,,MD,PhD says:

    Does “likely” seem to you an adequate scientific terminology? We are all sure it is not a marketing word.
    By the way you all know that analysts give the annual turnover of a successful monoclonal in Alzheimer at 2 billion dollars.

Leave a Comment

Your email address will not be published. Required fields are marked *